-

Thermo Fisher Scientific Elects New Director to Board

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Ruby Chandy has been elected to its board of directors, effective March 1, 2022. Ms. Chandy’s appointment will bring the total number of Thermo Fisher board members to 13.

Ms. Chandy was the president of the Industrial Division of Pall Corporation, a leading supplier of filtration, separation, and purification technologies. Previously, Ms. Chandy was chief marketing officer at the Dow Chemical Company and Rohm and Haas Corporation.

Ms. Chandy currently serves on the board of directors of DuPont de Nemours, Inc. (NYSE:DD) and Flowserve Corporation (NYSE: FLS). She also serves on the Advisory Board of Pritzker Private Capital, the MIT Sloan Americas Executive Board and is a mentor-in-residence at the University of Pennsylvania Penn Center for Innovation (PCI).

“I am pleased to welcome Ruby to the Thermo Fisher board and look forward to her insights gained through management positions across several industries,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Her experience will provide an important perspective as we work every day to fulfill our Mission of enabling our customers to make the world healthier, cleaner and safer.”

Ms. Chandy received a master’s degree in management from the MIT Sloan School, a master’s degree in materials science and engineering from Northwestern University and a bachelor’s degree in materials science and engineering from MIT.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care....

Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), two next-generation chemically-defined formulations that expand the Gibco™ Bacto™ CD portfolio to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli). As demand for plasmid DNA continues to surge to support expanding gene therapy and mRNA vaccin...

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...
Back to Newsroom